Abstract:It is well established that regular use of aspirin can reduce the relative risk of developing colorectal cancer. However, the impact of aspirin on survival after colorectal cancer diagnosis is not well understood. Studies have shown conflicting results. In this population‐based cohort study, the largest one to date, of all patients diagnosed with colorectal cancer in 2007‐2016, we found that aspirin was not associated with neither overall, colorectal cancer‐specific or disease‐free survival. Background Results from previous studies indicate that use of aspirin may improve colorectal cancer (CRC) survival. The aim of this study was to assess whether use of aspirin influences overall survival or CRC‐specific survival in an unselected cohort of patients diagnosed with CRC. Methods The study was performed using the Colorectal Cancer Data Base Sweden (CRCBaSe), a mega‐linkage originating from the Swedish Colorectal Cancer Register, with additional linkages to other national health care registers. All patients diagnosed with primary CRC stage I–III treated with curative surgery, aged 18–85 years at diagnosis, from 2007 through 2016 were identified. Information on low‐dose aspirin use was extracted from the Swedish Prescribed Drug Register. Exposure was defined as dispensed prescription for at least 6 months. Aspirin exposure was analyzed at the time of surgery (yes/no) and as a time‐varying exposure during follow‐up. Follow‐up was restricted to a maximum 6 years, to model 5‐year survival. Cox regression models were fitted to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Adjustments were performed for sex, age, year of diagnosis, Charlson comorbidity index, hypertension, and ASA score as potential confounders. Results A total of 32,195 patients diagnosed with CRC were included. 6764 (21%) were exposed to aspirin at the time of CRC surgery. The median time of follow‐up was 4.2 years. Aspirin use at the time of surgery was not associated with all‐cause (adjusted HR = 1.03, 95% CI: 0.97–1.08) nor CRC‐specific mortality (adjusted HR = 0.99, 95% CI: 0.91–1.07). Aspirin use during follow‐up was associated with increased all‐cause (adjusted HR = 1.09, 95% CI: 1.04–1.15) but not CRC‐specific mortality (adjusted HR = 0.98, 95% CI: 0.91–1.06). A CRC‐specific effect associated with aspirin was noted from approximately 3 years following surgery. Conclusions In this large nation‐wide cohort study there was no convincing association between aspirin use after CRC and OS or CRC‐specific survival.

Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study

Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year population cohort study in Hong Kong

Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study

Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan

Tu1959 - Helicobacter Pylori Eradication Therapy to Prevent Gastric Cancer in China Population: A Meta-Analysis

Potential beneficial effects of long-term aspirin use on the prevalence of colorectal cancer: a population-based study of the US Nationwide Inpatient Sample

New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice

Association of prophylactic low-dose aspirin use with all-cause and cause-specific mortality in cancer patients

The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial

Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study

Association between low-dose aspirin and the risk of gastric cancer and adenoma according to a family history of gastric cancer

Benefit and Harm of Aspirin on Mortality From Gastrointestinal Cancers Vs Bleeding in Helicobacter pylori-Eradicated Patients

Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice

Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study

Low-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway

Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials

Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis

A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma

Lack of Benefits for Prevention of Cardiovascular Disease with Aspirin Therapy in Type 2 Diabetic Patients - A Longitudinal Observational Study